Apellis Pharmaceuticals (NASDAQ: APLS) saw its stock price plummet 10.15% in pre-market trading on Thursday, despite reporting better-than-expected third-quarter results. This significant drop has left investors puzzled, given the company's apparent financial strength.

The biopharmaceutical company reported earnings per share of $1.67, surpassing analysts' expectations of $1.60. Revenue for the quarter came in at $458.6 million, also beating the forecast of $453.6 million. This represents a substantial increase from $196.8 million in the same quarter last year, indicating strong year-over-year growth.

Adding to the positive financial picture, Apellis reported a robust cash position of $479.2 million as of September 30, 2025. This healthy cash reserve typically signals financial stability and the ability to fund future operations and research.

The stark contrast between the company's solid financial performance and the stock's negative reaction suggests that investors may be focusing on other factors not immediately apparent in the earnings report. Possible explanations could include concerns about future guidance, market competition, or broader industry trends affecting biopharmaceutical companies. As the trading day progresses, investors will be closely watching for any additional information or analyst insights that might explain this unexpected market response.